BridgeBio has substantially boosted its development of the novel solution for ATTR-CM, leveraging the compound. Early patient results indicates promising outcomes for individuals diagnosed from the severe disease. This https://bridgebio888747.blogprodesign.com/63578137/firm-improves-attr-cm-management-through-the-therapy